MiRXES
Business Services · Singapore · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Tukang Innovation Grove #09-02 Jtc Medte...Phone Number
+65 68162931Website
www.mirxes.comRevenue
$53.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About MiRXES
MiRXES is a homegrown biotech company founded and based in Singapore since 2014. The company harness the company's world-leading microRNA research and technology platform to discover and incubate game-changing biotech applications across the medical, pharmaceutical, agricultural, and veterinary industries. Through the company's pioneering microRNA biomarker profiling efforts, the company works with the company's partners to develop revolutionary microRNA applicative uses that can solve real-world issues and accelerate them to market. With world-class R&D centers and manufacturing labs in Singapore, China, and the US, MiRXES is committed to building a global microRNA-based ecosystem with a strong network of clinicians, researchers, and corporates to transform innovative science into affordable, accurate, and accessible solutions that can eradicate disease and improve lives.Explore more
MiRXES Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MiRXES your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at MiRXES
Website visits: Recent activity has been detected on your website
Click to see if MiRXES had a recent Job posting/layoffs
Funding: Get notified immidiatlly once MiRXES has new funding data
Earning: See what the market has to say on MiRXES recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MiRXES, which may be a good buyer, showed buying intent in Masked Content Topic
Check if MiRXES has recently received funding, and reach out quickly before it becomes old news!
Check out if MiRXES is spiking on competitors!
Product Launch: Get notified when MiRXES launches new products
Recommended Actions
Find VP level buyers at MiRXES
Find 2 more new buyers
Company Profile Activity
Activity Insights
MiRXES is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MiRXES is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MiRXES.
MiRXES financials insights
Gather financial insights about MiRXES, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series C
$77M
2023
Series D
$50M
2025
Debt
$40M
MiRXES Tech Stack
A closer look at the technologies used by MiRXES
See more technologies
Most Recent Scoops
Open Position
Person-Based
Hiring Plans
MiRXES has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Cancer Screening, Cancer Detection, Oncology, Gastroenterology, and Medical Affairs.
Hiring Plans
Hiring Plans
MiRXES is hiring in Marketing for the first time in 12 months.
Hiring Plans
Hiring Plans
Hiring Plans
MiRXES News & Media
Singapore's Mirxes Announces NMPA Approval for GASTROClear™ in China, Paving the Way for Major Launch in Key Market
GASTROClear™ is the first non-invasive blood test approved for the screening of gastric cancer in China; Mirxes plans major expansion of operations in China Mirxes (SEHK:2629.HK) SINGAPORE, SINGAPORE, SINGAPORE, October 10, 2025 /EINPresswire.com/ -- …MiRXES Says China Will Be An Important Market
MiRXES Co-Founder & CEO Lihan Zhou says the Chinese market is key, as it gives his company the scale to bring down cost. The Singapore-based biotechnology startup made its Hong Kong initial public offering debut. He speaks with Haslinda Amin on "Insight with Haslinda Amin."CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion
- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets -...CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion
- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets -...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MiRXES
Sign Up For FreeTo access detailed company insights
MiRXES is a homegrown biotech company founded and based in Singapore since 2014. The company harness the company's world-leading microRNA research and technology platform to discover and incubate game-changing biotech applications across the medical, pharmaceutical, agricultural, and veterinary industries. Through the company's pioneering microRNA... Read More
